filmov
tv
DEBATE: ALK positive NSCLC - Front line therapy - Ceritinib
Показать описание
The Great Debates and Updates in Thoracic Malignancies 2015 conference focuses on controversial areas in the management of patients with lung and other thoracic cancers, with nationally-recognized thought leaders taking opposing sides on topics of interest to physicians and their patients.
Using didactic presentations in conjunction with lively and instructive debates, this exciting and comprehensive conference gives practicing clinicians a thorough analysis of all currently available and emerging data. Recognized thought leaders discuss and debate a variety of controversial topics, including management strategies for common mutations in lung cancer and utilization of molecular biomarker profile of the tumors to guide therapeutic decisions.
In this presentation, Dr. Jonathan W. Goldman argues in favor of ceritinib as the preferable front line therapy option for the treatment of ALK-positive Non-Small Cell Lung Cancer (NSCLC).
A continuing education program is offered as a supplement to this webcast at the following location:
© 2015 Imedex, LLC.
Using didactic presentations in conjunction with lively and instructive debates, this exciting and comprehensive conference gives practicing clinicians a thorough analysis of all currently available and emerging data. Recognized thought leaders discuss and debate a variety of controversial topics, including management strategies for common mutations in lung cancer and utilization of molecular biomarker profile of the tumors to guide therapeutic decisions.
In this presentation, Dr. Jonathan W. Goldman argues in favor of ceritinib as the preferable front line therapy option for the treatment of ALK-positive Non-Small Cell Lung Cancer (NSCLC).
A continuing education program is offered as a supplement to this webcast at the following location:
© 2015 Imedex, LLC.
0:11:38
DEBATE: ALK positive NSCLC - Front line therapy - Ceritinib
0:13:28
DEBATE: ALK positive NSCLC - Front line therapy - Crizotinib
0:03:34
ALK-positive NSCLC: the role of treatment selection and sequencing
0:01:27
Dr. Neal Debates Whether Alectinib Will Become the Standard Frontline Thera for ALK+ NSCLC
0:41:24
Dr Alastair Greystoke debates with Dr Tom Newsom-Davis “Lorlatinib – first or last?”
0:06:57
Case Based Panel Discussion 2019 ALK Positive Progression after Success on ALK Inhibitor
0:04:09
Charu Aggarwal, MD, MPH, describes her approach to managing an individual with ALK positive NSCLC
0:06:28
Case Based Panel Discussion - 2019 ALK Positive with Brain Mets, Radiation before ALK Inhibitor?
0:09:36
Case Based Panel Discussion 2019 Alk Positive First Line Treatment
0:08:51
ALK-Positive NSCLC
0:08:47
Dr Uma Dangi | Brigatinib versus Crizotinib in ALK Inhibitor Naive Advanced ALK Positive NSCLC
0:07:01
Case Based Panel Discussion 2.6 ALK Positive and High PDL1 First Line Treatment for Potentially Comp
0:04:14
Should a Second Generation ALK Inhibitor be First Line Therapy for Patients with ALK-Positive NSCLC?
0:06:04
Case Study: Progression on ALK Inhibitors in NSCLC
0:16:27
DEBATE: Molecular profiling beyond EGFR/ALK - Must be the standard
0:01:17
Dr. Christina Baik on Alectinib Versus Crizotinib in ALK-positive Lung Cancer
0:14:42
2020 CBPD LEVY - Stage IV NSCLC ALK Positive 74 YO Male with Brain Metastasis
0:11:14
Holistic management of patients with ALK-positive NSCLC
0:09:59
Case Based Panel Discussions - ALK Positive, Developing Resistance to ALK Inhibitors and Next Steps
0:01:11
Dr. Salgia on Crizotinib and Other TKIs in ALK-Positive NSCLC
0:01:39
Key findings of the ALEX study: Improved therapeutic options for ALK-positive NSCLC
0:03:13
Available Therapies for ALK-Rearranged NSCLC
0:05:32
How do you select appropriate therapy for ALK positive NSCLC in the first-line setting?
0:06:17
Case Based Panel Discussion –ALK Positive, High PD-L1:First Line Treatment for Competing Targets
Комментарии